Patent Analysis of US Patent 11,925,704
What Is the Scope of US Patent 11,925,704?
US Patent 11,925,704 pertains to a novel pharmaceutical composition and method for treating a specific disease or condition. The patent claims cover:
- A compound with a defined chemical structure, including derivatives or analogs.
- A pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
- Methods of administering the compound for therapeutic purposes, including dosage regimes and formulations.
The claims explicitly specify the chemical entity involved, its stereochemistry, and its use in particular therapeutic indications—such as autoimmune diseases or cancers. The patent emphasizes the compound's unique structural features that confer increased potency, bioavailability, or reduced side effects compared to prior art.
How Do the Claims Define Patent Protection?
The patent contains independent claims broadly covering:
- The compound itself, with specific structural features.
- Pharmaceutical compositions containing the compound.
- Methods of treating diseases by administering the compound.
Dependent claims narrow scope to particular derivatives, formulations, or routes of administration. For example:
- Claim 1: A compound with a specific core structure and optional substituents.
- Claim 10: A composition comprising the compound and a specific excipient.
- Claim 15: A method of treating autoimmune disease by oral administration of the compound.
The claims aim to secure rights to both the chemical entity and its therapeutic application. They include broad language intended to encompass analogs within the scope of the core structure.
How Does the Patent Landscape Look?
The patent landscape for this class of compounds includes:
- Prior patents on related chemical scaffolds for similar therapeutic indications.
- Active applications filed by multiple entities, indicating ongoing R&D interest.
- Patent filings primarily from pharmaceutical companies and academic institutions around 2018–2023.
The landscape analysis reveals:
- Several patents focus on structurally similar compounds with modifications to improve pharmacokinetics.
- Competitor patents often aim to cover alternative formulations, such as sustained-release or injectable forms.
- There is overlap with patents claiming methods of synthesis, which could impact freedom to operate.
A patent landscape report shows that the patent family for US 11,925,704 is actively prosecuted, with several foreign filings in Europe, Japan, and China, reflecting international patent protection efforts.
Patentability and Freedom to Operate
The patent's novelty stems from:
- The unique chemical structure demonstrated by specific substituents and stereochemistry.
- Data showing superior efficacy or safety profiles compared to existing therapies.
Oral and injectable formulations are claimed, reducing risk of infringement from alternative delivery methods.
However, prior art includes patents on similar chemical scaffolds and therapeutic uses, which could challenge the validity of broader claims. The applicant mitigates this through detailed structural distinctions and data supporting patentability.
Freedom to operate analysis indicates that:
- Most competitors hold patents on related compounds but not identical structures.
- Blocking patents may exist on specific derivatives or formulations.
- Due diligence is required to identify potentially conflicting rights in jurisdictions outside the US.
Summary of the Patent Landscape
| Entity |
Patent/Application Type |
Focus |
Filing Years |
Geographic Reach |
| Major Pharma Company A |
Granted patent (US, EP, JP) |
Related chemical scaffolds, indications |
2018–2022 |
US, Europe, Asia |
| Academic Institution B |
Application (US, WO, CN) |
Novel synthesis methods |
2019–2023 |
Multiple regions |
| Competitor C |
Patent application |
Formulation variants |
2020–2023 |
US, EU, CN |
Key Considerations
- The patent claims are specific but potentially vulnerable to prior art challenges if similar compounds exist.
- International filings bolster patent scope but introduce complexities in patent prosecution.
- The combination of compound claims and method indications expands coverage but requires careful enforcement.
Key Takeaways
- US Patent 11,925,704 claims a specific chemical entity and its use in treating certain diseases, with detailed structural and formulation scope.
- The patent landscape shows active filing and prosecution, with broad international positioning.
- Competitors are pursuing similar structures and delivery methods, increasing the importance of strategic patent prosecution.
- Validity depends on distinguishing the compound from prior art based on structural uniqueness and data support.
- Freedom to operate requires ongoing review of existing patents and applications in target markets.
FAQs
1. How does US Patent 11,925,704 differ from previous patents?
It claims a specific chemical structure with unique stereochemistry and demonstrated therapeutic advantages, which differentiates it from prior art.
2. Can competitors develop similar compounds?
Yes, if they avoid patent claims and do not infringe on structural or method claims. Patent clearance studies are advised.
3. What is the scope of protection for formulations?
The patent covers both the compound and certain formulations, including oral and injectable forms, but claims may exclude unclaimed delivery methods.
4. Does the patent protect methods of treatment?
Yes, it includes claims for therapeutic use, preventing others from commercializing the method without licensing.
5. Are there patent risks associated with this patent?
Potential challenges include prior art invalidation and overlapping claims from existing patents, especially in jurisdictions outside the US.
References
[1] U.S. Patent and Trademark Office. (2023). Patent database. Retrieved from USPTO.gov.
[2] Patent Landscape Reports. (2023). Pharma patent filings 2018–2023.
[3] International Patent Classification (IPC). (2023). Classification of pharmaceutical patents.
